Catalyst PharmaceuticalCPRX
CPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Employees: 167
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 22
25% more capital invested
Capital invested by funds: $1.52B [Q2] → $1.9B (+$378M) [Q3]
16% more funds holding
Funds holding: 270 [Q2] → 312 (+42) [Q3]
2.7% less ownership
Funds ownership: 83.32% [Q2] → 80.63% (-2.7%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 107
25% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]
61% less call options, than puts
Call options by funds: $610K | Put options by funds: $1.58M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
19%
upside
Avg. target
$33
39%
upside
High target
$36
53%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Baird Joel Beatty 55% 1-year accuracy 22 / 40 met price target | 19%upside $28 | Outperform Initiated | 4 Feb 2025 |
HC Wainwright & Co. Andrew Fein 35% 1-year accuracy 121 / 343 met price target | 48%upside $35 | Buy Maintained | 10 Jan 2025 |
B of A Securities Jason Gerberry 55% 1-year accuracy 11 / 20 met price target | 27%upside $30 | Buy Reiterated | 9 Jan 2025 |
Stephens & Co. Sudan Loganathan 32% 1-year accuracy 7 / 22 met price target | 48%upside $35 | Overweight Initiated | 18 Nov 2024 |
Truist Securities Joon Lee 49% 1-year accuracy 21 / 43 met price target | 53%upside $36 | Buy Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 13 articles about CPRX published over the past 30 days
Positive
Investors Business Daily
5 days ago
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.
Positive
Zacks Investment Research
1 week ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
GlobeNewsWire
1 week ago
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list.
Positive
Zacks Investment Research
2 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Neutral
GlobeNewsWire
2 weeks ago
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS").
Positive
Seeking Alpha
3 weeks ago
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver.
Positive
Zacks Investment Research
3 weeks ago
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Momentum in Catalyst (CPRX) Should Keep going
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Positive
Zacks Investment Research
3 weeks ago
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Investors Business Daily
3 weeks ago
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™